Can a Weekly Shot Replace Blood Draws for Polycythemia Vera?
Yes, for most adults with polycythemia vera who depend on regular phlebotomies, a newly approved once-weekly shot can replace them. The FDA cleared Mimrylo (rusfertide) on August 28, 2026. It's an add-on to standard care, not a cure, and hasn't yet been shown to prevent clots or extend life.
If you've been going in for regular phlebotomies to keep your red-cell mass in check, Mimrylo is the first drug that offers a real alternative to the needle without leaving you iron-starved. It's a hepcidin mimetic, given as a weekly shot you can do at home, and it works with aspirin and cytoreductive drugs like hydroxyurea or interferon, not in place of them.
What VERIFY actually showed
VERIFY randomized 293 adults with phlebotomy-dependent PV to weekly rusfertide or placebo, both added to whatever standard care they were already on. Placebo patients who crossed into the open-label extension reached comparable rates by weeks 40 to 52.
The earlier phase 2 REVIVE trial told the daily-life story more plainly: annualized phlebotomies fell from about nine to under one, and mean maximum hematocrit dropped from 50% to about 44.5%. Fewer needles, and hematocrit reliably below the 45% line clinicians target.
Why a shot can do the job of a bloodletting
Hepcidin is your body's iron traffic cop. It keeps iron from moving out of cells into the plasma. In PV, hepcidin runs too low for the amount of red-cell production happening, iron flows freely, and the JAK2-mutated marrow uses it to build too many red cells. Phlebotomy starves that marrow of iron by draining the iron from your whole body along with it, which is why frequent draws leave many people fatigued, foggy, and short of breath on exertion.
Rusfertide is a synthetic version of hepcidin. It locks iron away from red-cell production without depleting what you've got stored. A chemical phlebotomy that leaves your iron in the tank.
The limit is real. Hepcidin only touches red cells. Rusfertide does nothing to white cells or platelets, both of which independently drive clotting in PV, which is why the label positions it as an add-on to cytoreductive drugs rather than a replacement.
How it fits alongside what's already there
PV treatment has never been one drug. Which one, or which combination, depends on your risk category, how well the marrow responds, and what side effects you can live with.
| Treatment | How it's given | Effect on hematocrit and phlebotomies | Proven to cut clots or extend life? |
|---|---|---|---|
| Phlebotomy plus low-dose aspirin | Blood draw at the clinic, as needed | Standard way to hold hematocrit under 45%; often insufficient alone | Fewer clots when hematocrit stays under 45%; no direct survival trial |
| Hydroxyurea | Daily oral pill | Lowers red cells and also brings down white cells and platelets | Linked to lower thrombosis and mortality in large real-world cohorts |
| Ropeginterferon alfa-2b (Besremi) | Injection every two weeks | Holds hematocrit and can reduce JAK2 mutant burden over time | Linked to longer myelofibrosis-free and overall survival in observational data |
| Ruxolitinib (Jakafi) | Twice-daily pill | Controls hematocrit in hydroxyurea-resistant patients; also shrinks spleen | Trend toward fewer clots; not confirmed in randomized trials |
| Rusfertide (Mimrylo) | Weekly self-injection | Controls hematocrit and ends phlebotomies for most; no effect on white cells or platelets | Not yet shown to reduce clots or extend life |
The clot question rusfertide hasn't answered
The 45% target isn't arbitrary. In the CYTO-PV trial, adults with PV kept below 45% had cardiovascular death or major thrombosis in about 2.7% over roughly 31 months, versus 9.8% in the group allowed to sit between 45% and 50%. Rusfertide reliably hits the lower target. What it doesn't do is act on the other cells that drive clotting. A patient with excellent hematocrit control on Mimrylo may still need hydroxyurea or interferon if the risk profile is high.
The cautions matter. Injection-site reactions happened in about 56% of trial patients, some severe. You need a platelet count every two to four weeks, because rusfertide can push it higher. Anemia occurred in around 16%. It's contraindicated in pregnancy, and anyone who could become pregnant needs contraception during treatment and for at least 30 days after the last dose.
What it means today, and what would change the answer
For phlebotomy-dependent PV, Mimrylo is a genuine day-to-day advance: no more standing clinic appointments to have a pint removed, better iron status, and hematocrit control on a shot you give yourself once a week. Whether that steady control also translates into fewer strokes, fewer heart attacks, and more years of life is the harder question. Longer VERIFY follow-up and post-marketing data are what would move Mimrylo from a quality-of-life win to a disease-modifying one.